PERNIX THERAPEUTICS HOLDINGS, INC. Form SC 13G July 02, 2015
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934 (Amendment No.)*
Pernix Therapeutics Holdings, Inc. (Name of Issuer)
Common Stock, par value \$0.01 per share (Title of Class of Securities)
71426V108 (CUSIP Number)
June 22, 2015 (Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [_] Rule 13d-1(b)
[X] Rule 13d-1(c)
[_] Rule 13d-1(d)

^{*}The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No 71426V108

NAME OF

1. REPORTING

PERSONS

I.R.S.

IDENTIFICATION

NOS. OF

ABOVE

PERSONS

(ENTITIES

ONLY)

Armistice

Capital,

LLC

CHECK THE

APPROPRIATE

BOX IF A

MEMBER OF A

GROUP (SEE

INSTRUCTIONS)

(a) [_]

(b) [X]

SEC USE

ONLY

CITIZENSHIP

OR PLACE

OF

ORGANIZATION

Delaware

NUMBER OF **SHARES**

BENEFICIALLY

OWNED BY EACH

REPORTING PERSON

WITH

SOLE

5. VOTING

POWER

0

SHARED

6. VOTING **POWER**

3,400,000

SOLE

7. DISPOSITIVE **POWER**

0

SHARED

8. DISPOSITIVE **POWER**

3,400,000

AGGREGATE

AMOUNT

BENEFICIALLY

OWNED BY EACH

REPORTING

PERSON

3,400,000

CHECK

BOX IF

THE

AGGREGATE

AMOUNT

10.IN ROW (9)

EXCLUDES

CERTAIN

SHARES

(SEE

INSTRUCTIONS)

 $[_]$

PERCENT

OF CLASS

REPRESENTED 11. BY

AMOUNT

IN ROW (9)

5.7%

TYPE OF REPORTING 12. PERSON (SEE INSTRUCTIONS) OO

CUSIP No 71426V108

NAME OF

1. REPORTING

PERSONS

I.R.S.

IDENTIFICATION

NOS. OF

ABOVE

PERSONS

(ENTITIES

ONLY)

Armistice

Capital

Master

Fund, Ltd.

CHECK THE

APPROPRIATE

, BOX IF A

MEMBER OF A

GROUP (SEE

INSTRUCTIONS)

(a) [_]

(b) [X]

3. SEC USE ONLY

CITIZENSHIP

, OR PLACE

* OF

ORGANIZATION

Cayman

Islands

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY EACH

REPORTING PERSON

WITH

5. SOLE

VOTING

Edgar Filing: PERNIX THERAPEUTICS HOLDINGS, INC. - Form SC 13G **POWER** 0 **SHARED** 6. VOTING **POWER** 3,400,000 **SOLE** 7. DISPOSITIVE **POWER** 0 **SHARED** 8. DISPOSITIVE **POWER** 3,400,000 **AGGREGATE AMOUNT BENEFICIALLY** OWNED BY EACH **REPORTING PERSON** 3,400,000 **CHECK BOX IF** THE **AGGREGATE AMOUNT** 10. IN ROW (9) **EXCLUDES CERTAIN SHARES** (SEE **INSTRUCTIONS**) $[_]$

PERCENT OF CLASS REPRESENTED 11. BY AMOUNT IN ROW (9)

5.7%

TYPE OF REPORTING 12. PERSON (SEE

INSTRUCTIONS)

CO

CUSIP No 71426V108

NAME OF

1. REPORTING

PERSONS

I.R.S.

IDENTIFICATION

NOS. OF

ABOVE

PERSONS

(ENTITIES

ONLY)

Steven Boyd

CHECK THE APPROPRIATE

₂ BOX IF A

MEMBER OF A

GROUP (SEE

INSTRUCTIONS)

(a) [_]

(b) [X]

3. SEC USE ONLY

CITIZENSHIP

OR PLACE

4. OF

ORGANIZATION

United

States of

America

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON

WITH

SOLE

5. VOTING

POWER

0

SHARED

6. VOTING **POWER**

3,400,000

SOLE

7. DISPOSITIVE **POWER**

0

SHARED

8. DISPOSITIVE **POWER**

3,400,000

AGGREGATE

AMOUNT

BENEFICIALLY

OWNED BY EACH

REPORTING

PERSON

3,400,000

CHECK

BOX IF

THE

AGGREGATE

AMOUNT

10.IN ROW (9)

EXCLUDES

CERTAIN

SHARES

(SEE

INSTRUCTIONS)

 $[_]$

PERCENT

OF CLASS

REPRESENTED 11. BY

AMOUNT

IN ROW (9)

5.7%

TYPE OF REPORTING 12. PERSON (SEE INSTRUCTIONS) IN

CUSIP No 71426V108

Item 1. (a). Name of Issuer:

Pernix Therapeutics Holdings, Inc.

(b). Address of Issuer's Principal Executive Offices:

10 North Park Place, Suite 201 Morristown, New Jersey 07960

Item 2. (a). Name of Person Filing:

Armistice Capital, LLC Armistice Capital Master Fund Ltd. Steven Boyd

(b). Address of Principal Business Office, or if None, Residence:

Armistice Capital, LLC 623 Fifth Avenue, 31st Floor New York, New York 10022 United States of America

Armistice Capital Master Fund Ltd. c/o dms Corporate Services Ltd. 20 Genesis Close P.O. Box 314 Grand Cayman KY1-1104 Cayman Islands

Steven Boyd c/o Armistice Capital, LLC 623 Fifth Avenue, 31st Floor New York, New York 10022 United States of America

(c). Citizenship:

Armistice Capital, LLC – Delaware Armistice Capital Master Fund Ltd. – Cayman Islands Steven Boyd – United States of America

(d). Title of Class of Securities:

Common Stock, par value \$0.01 per share

(e). CUSIP Number:

71426V108

Item 3. If This Statement is filed pursuant to ss.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a
(a)[_]Broker or dealer registered under Section 15 of the Exchange Act (15 U.S.C. 78c).
(b)[_]Bank as defined in Section 3(a)(6) of the Exchange Act (15 U.S.C. 78c).
(c)[_]Insurance company as defined in Section 3(a)(19) of the Exchange Act (15 U.S.C. 78c).
(d)[_]Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
(e) [_] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)[_] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)[_]A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
(h)[_] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);
(i) $[_]$ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j) [_] Group, in accordance with $s.240.13d-1(b)(1)(ii)(J)$.
Item 4. Ownership.
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
(a) Amount beneficially owned:
Armistice Capital, LLC – 3,400,000 Armistice Capital Master Fund Ltd. – 3,400,000 Steven Boyd – 3,400,000
(b) Percent of class:
Armistice Capital, LLC – 5.7% Armistice Capital Master Fund Ltd. – 5.7% Steven Boyd – 5.7%

(c) Number of shares as to which the person has:

Armistice Capital, LLC

(i) Sole power to vote or to direct the vote	0 ,
(ii) Shared power to vote or to direct the vote	3,400,000,
(iii) Sole power to dispose or to direct the disposition of	0 ,
(iv) Shared power to dispose or to direct the disposition of	3,400,000.
Armistice Capital Master Fund Ltd.	
(i) Sole power to vote or to direct the vote	0 ,
(ii) Shared power to vote or to direct the vote	3,400,000,
(iii) Sole power to dispose or to direct the disposition of	0 ,
(iv) Shared power to dispose or to direct the disposition of	3,400,000.
Steven Boyd	
(i) Sole power to vote or to direct the vote	0 ,
(ii) Shared power to vote or to direct the vote	3,400,000,
(iii) Sole power to dispose or to direct the disposition of	0 ,
(iv) Shared power to dispose or to direct the disposition of	3,400,000.

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [_].

N/A

Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

N/A

Item Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the 7. Parent Holding Company.

If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

N/A

Item 8. Identification and Classification of Members of the Group.

If a group has filed this schedule pursuant to \$240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to \$240.13d-1(c) or \$240.13d-1(d), attach an exhibit stating the identity of each member of the group.

N/A

Item 9. Notice of Dissolution of Group.

Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.

N/A

Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

Steven Boyd

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

July 2, 2015
(Date)

Armistice Capital, LLC*
By: /s/ Steven Boyd

Steven Boyd

Managing Member
Armistice Capital Master Fund Ltd.
By: /s/ Steven Boyd

Steven Boyd

Director
/s/ Steven Boyd*

* The Reporting Persons disclaim beneficial ownership in the Common Stock, except to the extent of his or its pecuniary interest therein.

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

Exhibit A

AGREEMENT

The undersigned agree that this Schedule 13G dated July 2, 2015 relating to the Common Stock, par value \$0.01 per share, of Pernix Therapeutics Holdings, Inc. shall be filed on behalf of the undersigned.

Armistice Capital, LLC*

By: /s/ Steven Boyd

Steven Boyd

Managing Member

Armistice Capital Master Fund Ltd.

By: /s/ Steven Boyd

Steven Boyd

Director

/s/ Steven Boyd*

Steven Boyd

SK 27622 0001 6670911